AstraZeneca (AZN) Listing Harmonisation Update

AstraZeneca shareholders overwhelmingly approved (99.36% ‘for’) the special resolution to adopt new articles of association, officially greenlighting the harmonisation of its equity listing structure.

The goal is to offer flexibility to access the broadest available pool of capital, including in the US.

Critical Timetable for US Investors:

• Expected termination of ADR Programme and ADS delisting: February 2, 2026.
• Expected commencement of trading in AstraZeneca Shares and US Bonds on the NYSE: By 8:00 a.m. ET on Feb 2